These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33095855)

  • 1. Maternal Epstein-Barr Virus-Specific Antibodies and Risk of Infection in Ugandan Infants.
    Minab R; Bu W; Nguyen H; Wall A; Sholukh AM; Huang ML; Ortego M; Krantz EM; Irvine M; Casper C; Orem J; McGuire AT; Cohen JI; Gantt S
    J Infect Dis; 2021 Jun; 223(11):1897-1904. PubMed ID: 33095855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Biological Factors Associated With Early Epstein-Barr Virus Infection in Human Immunodeficiency Virus-Exposed Uninfected Infants in Eastern Uganda.
    Montoya-Ferrer A; Sanosyan A; Fayd'herbe de Maudave A; Pisoni A; Bollore K; Molès JP; Peries M; Tylleskar T; Tumwine JK; Ndeezi G; Gorgolas M; Nagot N; van de Perre P; Tuaillon E
    Clin Infect Dis; 2021 Mar; 72(6):1026-1032. PubMed ID: 32067040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus.
    Smith NA; Baresel PC; Jackson CL; Ogolla S; Toko EN; Heit S; Piriou E; Sumba OP; Middeldorp JM; Colborn KL; Rochford R
    J Infect Dis; 2019 Feb; 219(6):955-963. PubMed ID: 30312417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
    Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
    Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and virologic manifestations of primary Epstein-Barr virus (EBV) infection in Kenyan infants born to HIV-infected women.
    Slyker JA; Casper C; Tapia K; Richardson B; Bunts L; Huang ML; Maleche-Obimbo E; Nduati R; John-Stewart G
    J Infect Dis; 2013 Jun; 207(12):1798-806. PubMed ID: 23493724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
    Perez EM; Foley J; Tison T; Silva R; Ogembo JG
    Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses to vaccination among South African HIV-exposed and unexposed uninfected infants during the first 2 years of life.
    Reikie BA; Naidoo S; Ruck CE; Slogrove AL; de Beer C; la Grange H; Adams RC; Ho K; Smolen K; Speert DP; Cotton MF; Preiser W; Esser M; Kollmann TR
    Clin Vaccine Immunol; 2013 Jan; 20(1):33-8. PubMed ID: 23114697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
    Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
    Front Immunol; 2018; 9():932. PubMed ID: 29765376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
    Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
    J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus (EBV) infection in infancy.
    Chan KH; Tam JS; Peiris JS; Seto WH; Ng MH
    J Clin Virol; 2001 Apr; 21(1):57-62. PubMed ID: 11255098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.
    Herrman M; Mühe J; Quink C; Wang F
    J Virol; 2016 Feb; 90(3):1222-30. PubMed ID: 26559839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placental Transfer of Respiratory Syncytial Virus Antibody Among HIV-Exposed, Uninfected Infants.
    Patel SM; Jallow S; Boiditswe S; Madhi SA; Feemster KA; Steenhoff AP; Arscott-Mills T; Muthoga C; Ajibola G; Shapiro R; Shah SS; Cunningham CK; Kelly MS
    J Pediatric Infect Dis Soc; 2020 Jul; 9(3):349-356. PubMed ID: 31549157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced Transplacental Transfer of a Subset of Epstein-Barr Virus-Specific Antibodies to Neonates of Mothers Infected with Plasmodium falciparum Malaria during Pregnancy.
    Ogolla S; Daud II; Asito AS; Sumba OP; Ouma C; Vulule J; Middeldorp JM; Dent AE; Mehta S; Rochford R
    Clin Vaccine Immunol; 2015 Nov; 22(11):1197-205. PubMed ID: 26376931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice.
    Wei CJ; Bu W; Nguyen LA; Batchelor JD; Kim J; Pittaluga S; Fuller JR; Nguyen H; Chou TH; Cohen JI; Nabel GJ
    Sci Transl Med; 2022 May; 14(643):eabf3685. PubMed ID: 35507671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling of EBV Infection and Antibody Responses in Kenyan Infants With Different Levels of Malaria Exposure Shows Maternal Antibody Decay is a Major Determinant of Early EBV Infection.
    Reynaldi A; Schlub TE; Piriou E; Ogolla S; Sumba OP; Moormann AM; Rochford R; Davenport MP
    J Infect Dis; 2016 Nov; 214(9):1390-1398. PubMed ID: 27571902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments.
    Li F; Freed D; Heidecker G; Galli J; Durr E; Wang D
    Vaccine; 2022 Jun; 40(26):3638-3646. PubMed ID: 35577627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
    Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
    J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.